Quitting on the NHS

It seems strange that Nice has agreed that the NHS should pay for Champix, the new anti-smoking drug, while at the same time refusing to endorse, for example, Aricept, Exelon and Reminyl for those in the early stages of Alzheimer’s, and Avastin and Alimta for cancer. Cost-effective arguments don’t really wash — how does one cost the saving to the state of, for instance, a person with dementia being able to lead a relatively independent life and not having to rely on the state? If a 12-week course of Champix doesn’t work, will an addict be given a second chance, or a third or a fourth?